Stefano Realdon

Dr. Stefano Realdon

Centro Riferimento Oncologico CRO- IRCCS, Aviano, Italy
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Gastroenterology
Verified
Journal Article
Closed access
SMSilvia Mirandola
Silvia Mirandola
SRStefano Realdon
Stefano Realdon
JIJahangir Iqbal
Jahangir Iqbal
MGMartina Gerotto
Martina Gerotto
FPFrancesca Dal Pero
Francesca Dal Pero
AAAlfredo Alberti
Alfredo Alberti

Verified
Journal Article
Open access
PDF file
APAntonio Pellino
Antonio Pellino
SBStefano Brignola
Stefano Brignola
ERErika Riello
Erika Riello
MNMonia Niero
Monia Niero
SMSabina Murgioni
Sabina Murgioni
Matteo FassanMatteo Fassan
Matteo Fassan
The tight junction protein claudin-18 (CLDN18), is often expressed in various cancer types including gastric (GC) and gastroesophageal adenocarcinomas (GECs). In the last years, the isoform CLDN18.2 emerged as a potential drug target in metastatic GCs, leading to the development of monoclonal antibodies against this protein. CLDN18.2 is the dominant isoform of CLDN18 in normal gastric and gastric cancer tissues. In this work, we evaluated the immunohistochemical (IHC) profile of CLDN18 and its correlation with clinical and histopathological features including p53, E-cadherin, MSH2, MSH6, MLH1, PMS2, HER2, EBER and PD-L1 combined positive score, in a large real-world and mono-institutional series of advanced GCs (n = 280) and GECs (n = 70). The association of IHC results with survival outcomes was also investigated. High membranous CLDN18 expression (2+ and 3+ intensity ≥75%) was found in 117/350 (33.4%) samples analyzed. CLDN18 expression correlated with age <70 (p = 0.0035), positive EBV status (p = 0.002), high stage (III, IV) at diagnosis (p = 0.003), peritoneal involvement (p < 0.001) and lower incidence of liver metastases (p = 0.013). CLDN18 did not correlate with overall survival. The predictive value of response of CLDN18 to targeted agents is under investigation in several clinical trials and further studies will be needed to select patients who could benefit from these therapies.

22 April 2012 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MRMassimo Rugge
Massimo Rugge
Matteo FassanMatteo Fassan
Matteo Fassan
Marco Pizzi, MD PhDMarco Pizzi, MD PhD
Marco Pizzi, MD PhD
VZV. Zorzetto
V. Zorzetto
GMG. Maddalo
G. Maddalo
FFFabio Farinati
Fabio Farinati
Summary: Background: Among Western populations, the declining incidence of Helicobacter pylori infection coincides with a growing clinical impact of autoimmune gastritis.Aims: To describe the histological phenotype of autoimmune gastritis, also to test the prognostic impact of OLGA staging in the autoimmune setting.Methods: A single‐institutional series (spanning the years 2003–2011) of 562 consecutive patients (M:F ratio: 1:3.7; mean age = 57.6 ± 14.4 years) with serologically confirmed autoimmune gastritis underwent histology review and OLGA staging.Results: Helicobacter pylori infection was ascertained histologically in 44/562 cases (7.8%). Forty six biopsy sets (8.2%) featured OLGA stages III–IV; they included all four cases of incidental epithelial neoplasia (three intraepithelial and one invasive; three of these four cases had concomitant H. pylori infection). There were 230 (40.9%) and 139 (24.7%) cases, respectively, of linear and micro‐nodular enterochromaffin‐like cell hyperplasia; 19 (3.4%) type I carcinoids were detected. The series included 116 patients who underwent repeated endoscopy/biopsy sampling (mean time elapsing between the two procedures = 54 months; range 24–108). Paired histology showed a significant (P = 0.009) trend towards a stage progression [the stage increased in 25/116 cases (22%); it remained unchanged in 87/116 cases (75%)].Conclusions: In autoimmune gastritis, the cancer risk is restricted to high‐risk gastritis stages (III–IV), and is associated mainly with concomitant H. pylori infection. OLGA staging consistently depicts the time‐dependent organic progression of the autoimmune disease and provides key information for secondary gastric cancer prevention strategies.

8 March 2018 in International Journal of Food Sciences and Nutrition
Verified
Journal Article
Closed access
VGVincenza Gianfredi
Vincenza Gianfredi
TSTania Salvatori
Tania Salvatori
Milena VillariniMilena Villarini
Milena Villarini
Massimo MorettiMassimo Moretti
Massimo Moretti
DNDaniele Nucci
Daniele Nucci
SRStefano Realdon
Stefano Realdon
Colorectal cancer is the third most common cancer worldwide. Growing evidence shows that about 47% of cases of colorectal cancer can be prevented by a healthy lifestyle. We performed a systematic review and meta-analysis aimed to evaluate the association between dietary fibre intake and the risk of colon cancer. We performed a structured computer search on PubMed, including epidemiological studies reporting results of dietary fibre intake and risk of colon cancer in women or men. We compared subjects exposed to the highest versus the lowest consumption. The search strategy identified 376 papers. After screening, 25 datasets were included in our meta-analysis. Results suggest a protective role of dietary fibre intake on colon cancer risk ES = 0.74 (95% CI = 0.67-0.82), p value = .000, but, moderate statistical heterogeneity (χ2 = 42.73, p value = .011) was found. Due to the high mortality of colorectal cancer, it is important to identify effective preventive measures, especially those of a healthy lifestyle, such as a healthy diet.

1 July 2017 in Human Pathology
Verified
Journal Article
Closed access
RCRocco Cappellesso
Rocco Cappellesso
CLClaudio Luchini
Claudio Luchini
NVNicola Veronese
Nicola Veronese
MMMarcello Lo Mele
Marcello Lo Mele
ERErik Rosa-Rizzotto
Erik Rosa-Rizzotto
MRMassimo Rugge
Massimo Rugge

3 December 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
VGVincenza Gianfredi
Vincenza Gianfredi
DNDaniele Nucci
Daniele Nucci
AAAngela Abalsamo
Angela Abalsamo
Mattia AcitoMattia Acito
Mattia Acito
Milena VillariniMilena Villarini
Milena Villarini
SRStefano Realdon
Stefano Realdon
Breast cancer (BC) is the most common cancer in women and several factors are involved in its onset. Green tea (GT) has been shown to have potential beneficial effects on different types of cancer. The aim of this review was to evaluate the association between GT regular consumption and risk of BC in women. The risk of BC recurrence and risk of BC in relation to menopausal status were also evaluated. A literature search of PubMed, Scopus, and Web of Science was conducted. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed to perform the systematic review and meta-analysis. Full texts were downloaded for 40 studies; however, only 13 records were included in the meta-analysis. Eight were cohort studies and five were case-control studies. The pooled sample consisted of 163,810 people. An inverse statistically significant relationship between GT and BC risk, with an Odds Ratio (OR) = 0.85 ((95% CI = 0.80–0.92), p = 0.000)), was found. Egger’s linear regression test did not show a potential publication bias (intercept 0.33, t = 0.40, p = 0.695), which was also confirmed by the symmetry of the funnel plot. Moreover, no high statistical heterogeneity (Chi2 = 31.55, df = 13, I2 = 58.79%, p = 0.003) was found. The results of this meta-analysis showed a potential protective effect of GT consumption on BC, especially for BC recurrence.